Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Advertisement

Advertisement




Feb
13
Today In Oncology
ASCO and Conexiant Launch ASCO AI in Oncology
Demographic and Clinicopathologic Factors in Colorectal Adenoma Recurrence Risk
ASH Publishes Clinical Guidelines on AL Amyloidosis Diagnosis
FDA Approves TTFields Device for Pancreatic Cancer
Interval Cancer Rate With AI-Supported Mammography Screening
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo